{"doi":"10.1111/jne.70017","title":"Nuclear medicine and perspective thoughts in the diagnosis and treatment of pheochromocytoma and paraganglioma","abstract":"<jats:title>Abstract</jats:title><jats:p>Pheochromocytoma and paraganglioma (PPGL) are rare and life‐threatening tumors of the adrenal medulla and extra‐adrenal paraganglia, respectively. Management of PPGL depends on accurate diagnosis and treatment. This review provides a very comprehensive overview of nuclear medicine in PPGL with some of our perspective views on diagnostic challenges and pitfalls, treatment, and new phase studies. It describes nuclear medicine techniques including <jats:sup>64</jats:sup>Cu/<jats:sup>68</jats:sup>Ga‐DOTA‐SSA, <jats:sup>18</jats:sup>F‐FDOPA, <jats:sup>18</jats:sup>F‐FDG, <jats:sup>123</jats:sup>I‐MIBG, and some emerging molecular imaging agents and PRRT therapies, such as <jats:sup>203</jats:sup>Pb VMT‐α‐NET and <jats:sup>212</jats:sup>Pb VMT‐α‐NET targeted alpha therapy (TAT). It also provides insight into the use of proliferating cell nuclear antigen (PCNA) inhibitors in combination with therapeutics in aggressive/metastatic PPGL. Through a comprehensive review of the latest developments and clinical practice, this review aims to guide healthcare professionals in improving the diagnostic accuracy and therapeutic efficacy of PPGL.</jats:p>","journal":"Journal of Neuroendocrinology","year":2025,"id":626998,"datarank":0.26876392038420827,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.0,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":228267,"name":"Michael Aschner","orcid":"0000-0002-2619-1656","position":1,"is_corresponding":false},{"id":1622298,"name":"Emirhan Harbi","orcid":"0009-0005-9260-8316","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Nuclear medicine and perspective thoughts in the diagnosis and treatment of pheochromocytoma and paraganglioma","abstract":"<jats:title>Abstract</jats:title><jats:p>Pheochromocytoma and paraganglioma (PPGL) are rare and life‐threatening tumors of the adrenal medulla and extra‐adrenal paraganglia, respectively. Management of PPGL depends on accurate diagnosis and treatment. This review provides a very comprehensive overview of nuclear medicine in PPGL with some of our perspective views on diagnostic challenges and pitfalls, treatment, and new phase studies. It describes nuclear medicine techniques including <jats:sup>64</jats:sup>Cu/<jats:sup>68</jats:sup>Ga‐DOTA‐SSA, <jats:sup>18</jats:sup>F‐FDOPA, <jats:sup>18</jats:sup>F‐FDG, <jats:sup>123</jats:sup>I‐MIBG, and some emerging molecular imaging agents and PRRT therapies, such as <jats:sup>203</jats:sup>Pb VMT‐α‐NET and <jats:sup>212</jats:sup>Pb VMT‐α‐NET targeted alpha therapy (TAT). It also provides insight into the use of proliferating cell nuclear antigen (PCNA) inhibitors in combination with therapeutics in aggressive/metastatic PPGL. Through a comprehensive review of the latest developments and clinical practice, this review aims to guide healthcare professionals in improving the diagnostic accuracy and therapeutic efficacy of PPGL.</jats:p>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40042101","pmcid":null,"openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"bronze","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jne.70017","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jne.70017","host_type":"publisher"}],"fields_of_study":[],"mesh_terms":["Humans","Paraganglioma","Pheochromocytoma","Adrenal Gland Neoplasms","Radiopharmaceuticals","Nuclear Medicine"],"keywords":["Pheochromocytoma","Diagnosis and treatment","Paraganglioma","Nuclear Medicine"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T15:55:27.154974Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}